

Exela Pharma Sciences - Recall of sodium bicarbonate injection

- On October 13, 2022, <u>Exela Pharma Sciences</u> announced a voluntary consumer-level recall of forty-nine lots of <u>sodium bicarbonate 8.4%</u> injection because the product poses a potential safety concern with vial breakage and flying glass when pressurized while preparing the product for administration.
- This recalled product was distributed between December 16, 2021 and August 10, 2022. Refer to the press release for a list of recalled lots.
- Exela has received five reports of flying glass injuring skin, eye and/or other parts. There have been no reports of sterility failures.
- Sodium bicarbonate injection is indicated in the treatment of metabolic acidosis.
- Patients who have the recalled sodium bicarbonate injection should contact their physician or health care provider if they have experienced any problems that may be related to using the recalled products.
- Anyone with an existing inventory of the recalled product should stop use, distribution and quarantine the product immediately.
- Contact Exela by phone at 1-828-341-6118 or by email at recall@exela.us for more information.



At Optum, we help create a healthier world, one insight, one connection, one person at a time. All Optum trademarks and logos are owned by Optum, Inc., in the U.S. and other jurisdictions. All other trademarks are the property of their respective owners. This document contains information that is considered proprietary to Optum Rx and should not be reproduced without the express written consent of Optum Rx. RxNews® is published by the Optum Rx Clinical Services Department.